Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3658273 | 1.00 | KMT2A (0.47) | KMT2ASMN1; SMN2FFAR1MEN1KAT6A | |
| SCHEMBL2505230 | 0.89 | FFAR1 (0.42) | KMT2ASMN1; SMN2FFAR1MEN1KAT6A | |
| SCHEMBL2499334 | 0.89 | FFAR1 (0.42) | KMT2ASMN1; SMN2FFAR1MEN1KAT6A | |
| SCHEMBL3653937 | 0.84 | FFAR1 (0.56) | KMT2ASMN1; SMN2FFAR1MEN1 | |
| SCHEMBL3654240 | 0.84 | FFAR1 (0.56) | KMT2ASMN1; SMN2FFAR1MEN1 | |
| SCHEMBL2505637 | 0.82 | KMT2A (0.49) | KMT2ASMN1; SMN2FFAR1MEN1MMP12 | |
| SCHEMBL2505240 | 0.82 | KMT2A (0.49) | KMT2ASMN1; SMN2FFAR1MEN1MMP12 | |
| SCHEMBL12194079 | 0.81 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL12194078 | 0.81 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL2505233 | 0.81 | FFAR1 (0.47) | KMT2ASMN1; SMN2FFAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205548-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | Amgen, Inc (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | KMT2A 3040/4885SMN1; SMN2 4745/4885FFAR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.